Preclinical studies involving seralutinib have reported efficacy in preventing PAH progression and vascular remodeling, restored lung BMPR2 expression, reduced levels of pro-inflammatory biomarkers, improved hemodynamics, decreased NT-proBNP levels, and showed greater efficacy when compared with imatinib [56]. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.